8URV

Solution NMR structure of pro-IL-18

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	3D HCH NOESY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	100% D2O	50 mM	6.1	1 atm	298.1	Bruker AVANCE NEO 1000
2	3D HNH NOESY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE NEO 1000
3	3D NNH NOESY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE NEO 1000
4	2D NH HSQC	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
5	2D CH HSQC	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	100% D2O	50 mM	6.1	1 atm	298.1	Bruker AVANCE NEO 1000
6	3D HNCO	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
7	3D HN(CA)CO	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
8	3D CBCA(CO)NH	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
9	3D HNCACB	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
10	3D HNN	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
12	3D HBHA(CO)NH	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 800
11	3D C(CO)NH TOCSY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 600
13	3D H(CCO)NH TOCSY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 600
14	3D C(CA)NH TOCSY	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE III HD 600
15	2D CB(CGCD)HD	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	100% D2O	50 mM	6.1	1 atm	298.1	Bruker AVANCE NEO 1000
16	2D CB(CGCDCE)HE	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	100% D2O	50 mM	6.1	1 atm	298.1	Bruker AVANCE NEO 1000
17	2D CBCG(CE)HE	0.5 mM [U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	100% D2O	50 mM	6.1	1 atm	298.1	Bruker AVANCE III HD 800
18	2D CH CT-HSQC	0.5 mM [5% U-13C; U-15N] pro-interleukin-18, 20 mM MES, 50 mM potassium chloride, 10 mM DTT	97% H2O/3% D2O	50 mM	6.5	1 atm	298.1	Bruker AVANCE NEO 1000

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III HD	800
2	Bruker	AVANCE III HD	600
3	Bruker	AVANCE NEO	1000

NMR Refinement
Method	Details	Software
simulated annealing	FastRelax with constraints	Rosetta

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	I-PINE		Lee, Bahrami, Dashti, Eghbalnia, Tonelli, Westler and Markley
2	structure calculation	CYANA	3.98.15	Herrmann, Guntert and Wuthrich
3	refinement	Rosetta	3	Leaver-Fay et al.
4	peak picking	NMRFAM-SPARKY		Lee, Tonelli and Markley

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.